Verona Pharma plc (NASDAQ:VRNA - Get Free Report) CEO David Zaccardelli sold 208,696 shares of the business's stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $9.33, for a total value of $1,947,133.68. Following the transaction, the chief executive officer now directly owns 13,590,168 shares of the company's stock, valued at $126,796,267.44. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
David Zaccardelli also recently made the following trade(s):
- On Wednesday, May 28th, David Zaccardelli sold 157,704 shares of Verona Pharma stock. The stock was sold at an average price of $9.30, for a total value of $1,466,647.20.
- On Tuesday, May 27th, David Zaccardelli sold 33,600 shares of Verona Pharma stock. The stock was sold at an average price of $9.53, for a total value of $320,208.00.
- On Tuesday, April 29th, David Zaccardelli sold 90,360 shares of Verona Pharma stock. The stock was sold at an average price of $8.98, for a total value of $811,432.80.
Verona Pharma Trading Up 4.3%
Shares of Verona Pharma stock traded up $3.34 on Friday, hitting $80.83. 2,949,818 shares of the company's stock traded hands, compared to its average volume of 1,313,416. Verona Pharma plc has a one year low of $11.75 and a one year high of $81.73. The company has a debt-to-equity ratio of 0.93, a current ratio of 13.03 and a quick ratio of 12.88. The company has a fifty day moving average of $65.59 and a two-hundred day moving average of $57.00. The company has a market capitalization of $6.55 billion, a price-to-earnings ratio of -42.10 and a beta of 0.20.
Verona Pharma (NASDAQ:VRNA - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of ($0.22) by $0.49. The business had revenue of $98.65 million for the quarter, compared to the consensus estimate of $41.47 million. As a group, sell-side analysts expect that Verona Pharma plc will post -1.95 earnings per share for the current year.
Analyst Ratings Changes
A number of brokerages recently weighed in on VRNA. TD Cowen began coverage on Verona Pharma in a research report on Monday, April 28th. They set a "buy" rating and a $100.00 price objective on the stock. Roth Capital set a $83.00 price objective on Verona Pharma in a research report on Friday, February 28th. Wells Fargo & Company boosted their price objective on Verona Pharma from $93.00 to $107.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 30th. HC Wainwright upped their price target on Verona Pharma from $75.00 to $85.00 and gave the company a "buy" rating in a research report on Wednesday, April 30th. Finally, Canaccord Genuity Group upped their price target on Verona Pharma from $44.00 to $72.00 and gave the company a "buy" rating in a research report on Wednesday, February 12th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Verona Pharma presently has a consensus rating of "Buy" and a consensus price target of $81.50.
View Our Latest Report on VRNA
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. RTW Investments LP purchased a new stake in shares of Verona Pharma in the fourth quarter worth approximately $84,568,000. Adage Capital Partners GP L.L.C. raised its stake in shares of Verona Pharma by 381.9% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,631,000 shares of the company's stock worth $103,552,000 after purchasing an additional 1,292,575 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Verona Pharma by 61.0% in the fourth quarter. Wellington Management Group LLP now owns 3,025,241 shares of the company's stock worth $140,492,000 after purchasing an additional 1,146,609 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Verona Pharma in the first quarter worth approximately $58,716,000. Finally, Darwin Global Management Ltd. purchased a new stake in shares of Verona Pharma in the fourth quarter worth approximately $37,637,000. 85.88% of the stock is owned by institutional investors and hedge funds.
About Verona Pharma
(
Get Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Featured Stories
Before you consider Verona Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma wasn't on the list.
While Verona Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
